We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
-12.56%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$212M
AUM Growth
-$64.6M
Cap. Flow
-$15M
Cap. Flow %
-7.08%
Top 10 Hldgs %
72.97%
Holding
103
New
14
Increased
10
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2M
2
MYGN icon
Myriad Genetics
MYGN
+$1.92M
3
COGT icon
Cogent Biosciences
COGT
+$1.67M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.38M
5
TECX
Tectonic Therapeutic
TECX
+$1.3M

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$5.56M
2
VRNA
Verona Pharma
VRNA
+$4.26M
3
ICLO icon
Invesco AAA CLO Floating Rate Note ETF
ICLO
+$3.36M
4
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$1.96M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.57M

Sector Composition

Rank Sector Weight
1 Healthcare 33.25%
2 Materials 20.41%
3 Financials 19.12%
4 Miscellaneous 15.29%
5 Communication Services 8.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLMT icon
1
Calumet Specialty Products
CLMT
$4.74B
$41.8M 19.73%
3,297,194
-354,167
-10% -$5.56M
APO icon
2
Apollo Global Management
APO
$77.8B
$30.8M 14.54%
225,000
– –
JAAA icon
3
Janus Henderson AAA CLO ETF
JAAA
$30.4B
$28M 13.2%
551,763
-38,634
-7% -$1.96M
GOOG icon
4
Alphabet (Google) Class C
GOOG
$4.1T
$17.5M 8.27%
112,220
– –
DCGO icon
5
DocGo
DCGO
$38.4M
$8.11M 3.82%
3,070,850
– –
PFE icon
6
Pfizer
PFE
$158B
$6.45M 3.04%
254,537
– –
XERS icon
7
Xeris Biopharma Holdings
XERS
$1.55B
$6.09M 2.88%
1,110,000
+110,000
+11% +$444K
VRNA
8
DELISTED
Verona Pharma
VRNA
$5.59M 2.64%
88,000
-71,300
-45% -$4.26M
JPM icon
9
JPMorgan Chase
JPM
$940B
$5.15M 2.43%
20,985
– –
CPRX
10
DELISTED
Catalyst Pharmaceutical
CPRX
$5.14M 2.43%
212,000
+2,000
+1% +$45K
TVTX icon
11
Travere Therapeutics
TVTX
$6.23B
$4.09M 1.93%
228,000
– –
PTGX icon
12
Protagonist Therapeutics
PTGX
$9.44B
$3.68M 1.73%
76,000
+23,632
+45% +$990K
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.32B
$3.45M 1.63%
460,000
+20,000
+5% +$161K
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$3.34M 1.57%
426,000
+79,096
+23% +$662K
ESGR
15
DELISTED
Enstar Group
ESGR
$2.49M 1.18%
7,500
– –
ARDX icon
16
Ardelyx
ARDX
$973M
$2.42M 1.14%
493,807
-118,463
-19% -$636K
OABI icon
17
OmniAb
OABI
$616M
$2.36M 1.11%
982,336
-112,169
-10% -$367K
CSX icon
18
CSX Corp
CSX
$90.8B
$2.06M 0.97%
70,000
– –
AB icon
19
AllianceBernstein
AB
$3.42B
$1.84M 0.87%
48,000
– –
ICLO icon
20
Invesco AAA CLO Floating Rate Note ETF
ICLO
$573M
$1.8M 0.85%
70,502
-130,985
-65% -$3.36M
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$1.47B
$1.74M 0.82%
+48,000
New +$2M
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.78B
$1.57M 0.74%
128,000
– –
MYGN icon
23
Myriad Genetics
MYGN
$304M
$1.42M 0.67%
+160,000
New +$1.92M
COGT icon
24
Cogent Biosciences
COGT
$6.12B
$1.28M 0.6%
+213,302
New +$1.67M
CLOZ icon
25
Panagram BBB-B CLO ETF
CLOZ
$798M
$1.27M 0.6%
47,807
– –
1
2 3 4 5

Similar funds

GFL
Granite FO LLC Bedford, New Hampshire $189M AUM 56.18% 1-Year Est. Return
SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FSBI
Fearless Solutions (Best Invest) San Antonio, Texas $189M AUM 32.69% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM

David M. Knott Jr's Q1 2025 Portfolio in Review

As of Q1 2025, David M. Knott Jr held 103 positions worth $212M, down 23% from $277M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

David M. Knott Jr withdrew a net $15M in Q1 2025, closing 19 positions and reducing 14 holdings. Its most notable exit was Viking Therapeutics, an estimated $1.57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 26% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in Ultragenyx Pharmaceutical worth $1.74M.

  • David M. Knott Jr's largest Q1 2025 buy was Ultragenyx Pharmaceutical: 48,000 shares worth $1.74M.
  • David M. Knott Jr added most to Protagonist Therapeutics in Q1 2025, an estimated $990K increase.
  • David M. Knott Jr's biggest Q1 2025 reduction was Calumet Specialty Products, cutting an estimated $5.56M.
  • David M. Knott Jr fully exited Viking Therapeutics in Q1 2025, selling an estimated $1.57M.
  • David M. Knott Jr's ten largest holdings make up 73% of its $212M portfolio in Q1 2025.
  • David M. Knott Jr opened 14 new positions and closed 19 in Q1 2025.
  • David M. Knott Jr's portfolio value fell 23% quarter-over-quarter to $212M.

Based on David M. Knott Jr's 13F filing for Q1 2025, filed 12 May 2025.